Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021
Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021
SUMMARY
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 8 molecules. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Undisclosed, Cardiovascular, Dermatology, Immunology, Infectious Disease and Oncology which include indications Migraine, Unspecified, Trigeminal Neuralgia (Tic Douloureux), Coronavirus Disease 2019 (COVID-19), Pain, Pancreatic Cancer, Psoriasis, Resistant Hypertension, Rosacea and Traumatic Brain Injury.
Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 8 molecules. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Undisclosed, Cardiovascular, Dermatology, Immunology, Infectious Disease and Oncology which include indications Migraine, Unspecified, Trigeminal Neuralgia (Tic Douloureux), Coronavirus Disease 2019 (COVID-19), Pain, Pancreatic Cancer, Psoriasis, Resistant Hypertension, Rosacea and Traumatic Brain Injury.
Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
- The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
AbbVie Inc
Adepthera LLC
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Modulus Oncology Ltd
Shanghai Junshi Bioscience Co Ltd
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
atogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0022562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant sulfate ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHF-1036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CALCRL and RAMP for Resistant Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zavegepant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Sosei Heptares initiates phase 1 trial with novel small-molecule CGRP antagonist under collaboration with Biohaven
Jun 23, 2021: Amgen announces approval Of Aimovig (frenumab) in Japan for the suppression of onset of migraine attacks in adults
Jun 03, 2021: Biohaven announces presentations on Zavegepant at the 2021 virtual annual scientific meeting of the American Headache Society
Jun 03, 2021: Biohaven showcases CGRP-antagonist franchise data including Nurtec ODT (rimegepant), now approved to treat and prevent migraine attacks, and presentations at the 2021 virtual annual scientific meeting of the American Headache Society
May 27, 2021: FDA approves Biohaven's Nurtec ODT (Rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment
May 14, 2021: Biohaven's Nurtec ODT signs as primary partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
Apr 13, 2021: Biohaven announces presentations on Zavegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 13, 2021: Biohaven announces presentations on rimegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 07, 2021: AbbVie to present data on Atogepant at the 2021 American Academy of Neurology (AAN) Annual Meeting
Mar 30, 2021: U.S. FDA accepts AbbVie's New Drug Application for Atogepant for the preventive treatment of Migraine
Mar 30, 2021: Biohaven initiates enrolment in migraine treatment trial
Mar 11, 2021: Biohaven's nurtec ODT approved in United Arab Emirates for acute treatment of migraine
Mar 10, 2021: Biohaven's Nurtec ODT approved in Israel for acute treatment of migraine
Jan 25, 2021: Biohaven announces preliminary 4Q2020 net product revenue for NURTEC ODT
Jan 18, 2021: Biohaven signs Cody Ware as driver for Nurtec ODT Chevrolet for the 2021 NASCAR Cup series season
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
AbbVie Inc
Adepthera LLC
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Modulus Oncology Ltd
Shanghai Junshi Bioscience Co Ltd
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
atogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0022562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant sulfate ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHF-1036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CALCRL and RAMP for Resistant Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zavegepant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Sosei Heptares initiates phase 1 trial with novel small-molecule CGRP antagonist under collaboration with Biohaven
Jun 23, 2021: Amgen announces approval Of Aimovig (frenumab) in Japan for the suppression of onset of migraine attacks in adults
Jun 03, 2021: Biohaven announces presentations on Zavegepant at the 2021 virtual annual scientific meeting of the American Headache Society
Jun 03, 2021: Biohaven showcases CGRP-antagonist franchise data including Nurtec ODT (rimegepant), now approved to treat and prevent migraine attacks, and presentations at the 2021 virtual annual scientific meeting of the American Headache Society
May 27, 2021: FDA approves Biohaven's Nurtec ODT (Rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment
May 14, 2021: Biohaven's Nurtec ODT signs as primary partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
Apr 13, 2021: Biohaven announces presentations on Zavegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 13, 2021: Biohaven announces presentations on rimegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 07, 2021: AbbVie to present data on Atogepant at the 2021 American Academy of Neurology (AAN) Annual Meeting
Mar 30, 2021: U.S. FDA accepts AbbVie's New Drug Application for Atogepant for the preventive treatment of Migraine
Mar 30, 2021: Biohaven initiates enrolment in migraine treatment trial
Mar 11, 2021: Biohaven's nurtec ODT approved in United Arab Emirates for acute treatment of migraine
Mar 10, 2021: Biohaven's Nurtec ODT approved in Israel for acute treatment of migraine
Jan 25, 2021: Biohaven announces preliminary 4Q2020 net product revenue for NURTEC ODT
Jan 18, 2021: Biohaven signs Cody Ware as driver for Nurtec ODT Chevrolet for the 2021 NASCAR Cup series season
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Adepthera LLC, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
Pipeline by Modulus Oncology Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Adepthera LLC, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
Pipeline by Modulus Oncology Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
